The effects of interferon‐β on interleukin‐10 in multiple sclerosis patients
- 3 February 2005
- journal article
- clinical trial
- Published by Wiley in European Journal of Neurology
- Vol. 12 (3), 208-211
- https://doi.org/10.1111/j.1468-1331.2004.00986.x
Abstract
The incidence of the neuropathological lesions and the severity of the clinical symptoms in multiple sclerosis (MS) are correlated with the amount of the transferred autoreactive T cells. The balance between the T helper 1 (Th1) and T helper 2 (Th2) cytokine phenotypes may affect the activity of the disease in MS patients. Interleukin-10 (IL-10) is a cytokine secreted by Th2 cells. Thus, it has been thought that inducing IL-10 may have therapeutic effects in the treatment of MS patients. In this study, in order determine whether different types of prophylaxis change the secretion of IL-10, we measured the levels of IL-10 in relapsing-remitting type multiple sclerosis (RRMS) patients receiving interferon-beta 1b (IFN-beta 1b) or azathioprine (AZA). Our study consisted of RRMS patients (n=45) and healthy subjects (n=15) as control group. Patients were categorized into three groups as those receiving either IFN-beta 1b or AZA and those not receiving prophylaxis. Each group was compared with the control group. Serum IL-10 levels were determined using ELISA method. IL-10 levels of those receiving IFN-beta 1b were found to be significantly higher than that of other groups. These results support that the ability of inducing anti-inflammatory cytokine IL-10 plays a role in the clinical advantage of IFN-beta 1b in MS treatment.Keywords
This publication has 26 references indexed in Scilit:
- Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon‐α therapyJournal of Medical Virology, 2001
- Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive diseaseMultiple Sclerosis Journal, 2001
- The effect of interferon β-1b on lymphocyte-endothelial cell adhesionJournal of Neuroimmunology, 1996
- Interferon beta induces interleukin‐10 expression: Relevance to multiple sclerosisAnnals of Neurology, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Interferon effects on interleukin-10 secretion Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patientsJournal of Neuroimmunology, 1995
- Tumor necrosis factor‐α messenger RNA expression in patients with relapsing‐remitting multiple sclerosis is associated with disease activityAnnals of Neurology, 1995
- Interleukin‐10 prevents experimental allergic encephalomyelitis in ratsEuropean Journal of Immunology, 1994
- Overview of azathioprine treatment in multiple sclerosisThe Lancet, 1991
- Cyclosporine versus azathioprine in the long‐term treatment of multiple sclerosis—results of the german multicenter studyAnnals of Neurology, 1988